News

The Manila Times11m
Palvella Therapeutics Granted Sixth U.S. Patent Covering 0.1-20% Anhydrous Compositions of Rapamycin and Other mTOR Inhibitors
Palvella Therapeutics, Inc. (Palvella), a clinical-stage biopharmaceutical company focused on developing and commercializing ...
The Manila Times11m
Moleculin Receives Positive FDA Feedback on Pediatric Study Plan for Annamycin in Children with R/R AML
FDA recommends inclusion of patients as young as 6 months - younger than Moleculin had proposed - to be allowed in the ...
Biogen Inc.: Biogen Initiates Phase 3 Pediatric Study of Omaveloxolone for the Treatment of Friedreich Ataxia
Global Phase 3 BRAVE study will evaluate the efficacy and safety of omaveloxolone in children 2 to BRAVE study will explore the potential of omaveloxolone to address the critical unmet need of the ped ...
BERNAMA44m
Death Of Family Of Four: Trailer Driver Gets 8 Years’ Jail, RM80,000 Fine
TAIPING, June 18 (Bernama) -- A trailer driver was sentenced to eight years in prison and fined RM80,000 by the High Court ...